Render Target: STATIC
Render Timestamp: 2024-10-31T11:04:33.590Z
Commit: 23cb9f61fe67e1e9093fd644a533c4ff516a6463
XML generation date: 2024-09-30 01:58:24.841
Product last modified at: 2024-10-24T12:15:11.021Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

VEGF-A (E9X8Q) Rabbit mAb #50661

Filter:
  • WB
  • IP

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 16, 20, 23, 26
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:200

    Storage


    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    VEGF-A (E9X8Q) Rabbit mAb recognizes endogenous levels of total VEGF-A protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the amino terminus of human VEGF-A protein.

    Background

    Vascular endothelial growth factor-A (VEGF-A; formerly VEGF) belongs to the VEGF/PDGF family of growth factors that play a critical role in promoting vascular development. VEGF-A is primarily known for its function in promoting angiogenesis, the process by which new blood vessels are sprouted from pre-existing blood vessels. VEGF-A has eight isoforms, derived from differentially spliced mRNA variants encoded by the VEGF-A gene (1). All isoforms contain a conserved receptor binding domain, but differ in their C-terminal domains that regulate binding to components in the extracellular matrix. VEGF-A is secreted by multiple cell types, including fibroblasts, macrophages, and some tumor cells (1). Binding of VEGF-A to its cognate receptors (VEGFR2 and to a lesser extent VEGFR1) on the endothelial cell surface activates the receptor and initiates downstream signaling, resulting in endothelial cell proliferation, survival, migration, and changes to vascular permeability, all crucial processes for angiogenesis (3). Tumor cells have been shown to respond to hypoxia by increasing VEGF-A mRNA expression. Increased secretion of VEGF-A in the tumor microenvironment stimulates angiogenesis to further promote tumor progression (4). In addition to promoting tumor angiogenesis, VEGF-A has also been shown to play an important role in normal tissue development, tissue regeneration, tumor cell proliferation, neovascular eye diseases, and cancer immunity (2,5). For this reason, targeting angiogenesis via the VEGF-A pathway has been a major focus in cancer therapeutics research.
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.